Compare F5 Inc (FFIV) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Mesoblast Limited — how do they compare? F5 Inc trades at $402.08 (market cap $23.79B), while Mesoblast Limited trades at $18.78 (market cap $2.31B). The key difference: F5 Inc is far larger — about 10.3× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| FFIV | MESO | |
|---|---|---|
Market Cap | $23.79B | $2.31B |
Sector | Technology | Technology |
52-Week High | $431.26 | $20.96 |
52-Week Low | $223.99 | $11.35 |
Enterprise Value | $22.60B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 Networks (FFIV) trades at $419.00, down 2.84% on the day, but remains in a bullish technical trend above key support levels. The company demonstrates strong fundamental momentum with revenue growth to $3.09B in 2025 and consistent earnings beats, including a recent Q1 2026 EPS of $3.90 against a $3.46 expectation. Recent news highlights strategic expansion into AI security, including the acquisition of SurePath AI (GeekWire, 2026-06-26).
The outlook is supported by robust profitability and strategic positioning in application security, but elevated valuation multiples (P/E 34.61, P/S 7.6) and a high current price relative to the analyst consensus target of $397.00 present near-term valuation risk. The primary investment opportunity lies in the company's execution on its AI security platform growth, while risks include competitive pressures and the stock's premium pricing.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
